Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 13/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20187520 | 0.84 | KDM4E (0.46) | MEN1KMT2ATRPA1KDM4EADORA2B | |
| SCHEMBL18704122 | 0.81 | ADORA2B (0.52) | TRPA1ADORA2B | |
| SCHEMBL18704017 | 0.80 | SMN1; SMN2 (0.56) | KMT2ATRPA1KDM4EADORA2BRXFP1 | |
| Hydrochloric Acid SCHEMBL18742217 | 0.80 | ADORA2B (0.51) | TRPA1ADORA2B | |
| SCHEMBL22210245 | 0.77 | TRPA1 (0.38) | TRPA1 | |
| SCHEMBL20203276 | 0.76 | TRPA1 (0.41) | TRPA1 | |
| SCHEMBL21367675 | 0.76 | TRPA1 (0.58) | MEN1KMT2ATRPA1KDM4EALDH1A1 | |
| SCHEMBL20203241 | 0.72 | RXFP1 (0.39) | TRPA1ADORA2BRXFP1 | |
| SCHEMBL20203174 | 0.69 | ADORA2A (0.48) | TRPA1ADORA2BALDH1A1 | |
| SCHEMBL23246540 | 0.69 | ADORA2B (0.52) | MEN1KMT2ATRPA1ADORA2BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10913742-B2 | Oxadiazolones as transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-20190284189-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913742-B2 | Oxadiazolones as transient receptor potential channel inhibitors | TRPA1, TRPV1, TRPV3 | MEN1 4587/4885KMT2A 4562/4885TRPA1 1/4885 |
| US-20190284189-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, TRPV3 | MEN1 4587/4885KMT2A 4562/4885TRPA1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.